Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Herein is disclosed an emulsion comprising a silicone pre-elastomer, glycerol, a cyclodextrin, and a metal catalyst suitable for use in the polymerization of the silicone pre-elastomer, a silicone elastomer formed from the emulsion and dermal patches for release of octenidine formed from the silicone elastomer. Further there is dis-closed methods of forming the emulsion, the silicone elastomer and the dermal patch.

An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.

A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.

A method of inverting the phase arrangement of the silicone phase and the acrylic phase in a silicone acrylic hybrid composition, the silicone acrylic hybrid composition comprising: a) a silicone acrylic hybrid pressure sensitive adhesive, and b) a solvent, wherein the phase arrangement of the silicone phase and the acrylic phase in the initial silicone acrylic hybrid composition forming a continuous external phase and a discontinuous internal phase is determined by the solvent, comprising the step of adding an activator to the silicone acrylic hybrid composition, wherein the activator a) is liquid at 20° C. and 1013 mbar, b) has a boiling point which is higher than the boiling point of the solvent and/or has a vapor pressure at 20° C. which is lower than the vapor pressure of the solvent contained in the silicone acrylic hybrid composition, and c) provides better dissolution properties for the inner phase of the initial silicone acrylic hybrid composition than the solvent contained in the silicone acrylic hybrid composition.

In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan δ) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.

The present invention relates to a transdermal therapeutic system for the cutaneous administration of phenprocoumon, comprising an active-substance-impermeable backing layer, an adhesive matrix layer and optionally a removable protective layer, the adhesive matrix layer containing phenprocoumon and at least one matrix polymer, and the content of phenprocoumon in the matrix polymer being ≤7.5 wt. %. By virtue of the low load, it is ensured that the system releases the active ingredient substantially in high release rates, because high thermodynamic activity of the active ingredient is achieved. The present invention also relates to a method for producing a corresponding transdermal therapeutic system.

The present disclosure relates to methods of treating cancer and, more particularly, an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, in a dosage form for transdermal delivery in the treatment of cancer.